ResearcherCapital Medical UniversityNo recent work listed

Rui Yan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5052-4377; OpenAlex author ID A5010620212. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2020: 1 paper · 2021: none · 2022: 1 paper

Papers 2

Inhibition of DCLK1 kinase reverses epithelial-mesenchymal transition and restores T-cell activity in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.tranon.2021.101317 ↗
Inhibition of DCLK1 down-regulates PD-L1 expression through Hippo pathway in human pancreatic cancer. Co-author DOI 10.1016/j.lfs.2019.117150 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Yang Ge · 2 shared papers, 2020–2022 · strength 0.28
- Paper Inhibition of DCLK1 kinase reverses epithelial-mesenchymal transition and restores T-cell activity in pancreatic ductal… DOI 10.1016/j.tranon.2021.101317 ↗
- Paper Inhibition of DCLK1 down-regulates PD-L1 expression through Hippo pathway in human pancreatic cancer. DOI 10.1016/j.lfs.2019.117150 ↗
Guangyu An · 2 shared papers, 2020–2022 · strength 0.28
- Paper Inhibition of DCLK1 kinase reverses epithelial-mesenchymal transition and restores T-cell activity in pancreatic ductal… DOI 10.1016/j.tranon.2021.101317 ↗
- Paper Inhibition of DCLK1 down-regulates PD-L1 expression through Hippo pathway in human pancreatic cancer. DOI 10.1016/j.lfs.2019.117150 ↗
Xiaona Fan · 1 shared paper, 2022 · strength 0.16
- Paper Inhibition of DCLK1 kinase reverses epithelial-mesenchymal transition and restores T-cell activity in pancreatic ductal… DOI 10.1016/j.tranon.2021.101317 ↗
Yuanyuan Zhang · 1 shared paper, 2022 · strength 0.16
- Paper Inhibition of DCLK1 kinase reverses epithelial-mesenchymal transition and restores T-cell activity in pancreatic ductal… DOI 10.1016/j.tranon.2021.101317 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.